Citations

Clear

4439 citation(s) found for "Lee, E".

Metabolic reprogramming of pathogenic CD4 + T helper cells attenuates inflammatory bowel disease in mice
Mishra, Shravan K , Abdelrahman, Leena M , Kim Lee, Hyun Se , Valenzuela-Pérez, Lucía , Manna, Dina Faeq , Abram, Tanner J , Ali, Lama Mohamed , Davidson, Heidi M , Hassan, Omar M , Faubion, William A. , Hirsova, Petra , Bamidele, Adebowale O

Mayo Clinic

Science Signaling | October 6, 2026 | Volume: 19 | Issue: 958 | Pages: No page available

10.1126/scisignal.aeb2392 | PMID 42837442 Get It

CD4 + effector T helper 1 (T H 1) cells drive inflammatory bowel disease (IBD). Here, we investigated how integrated signaling, metabolic, and epigenetic programs sustain their pathogenic persistence. We found that enforcing mitochondrial pyruvate metabolism with methyl pyruvate (MePyr) suppressed T H 1 cell effector function and induced the acquisition of a regulatory-like phenotype. MePyr suppressed the activity of glycogen synthase kinase 3β (GSK3β), promoting a metabolic shift from glycolysis toward oxidative phosphorylation (OXPHOS) and limiting the accumulation of intracellular acetyl-CoA. This metabolic reprogramming decreased histone H3 acetylation at genes encoding inflammatory cytokines, thereby decreasing T H 1 cell–associated gene expression. Restoration of inflammatory cytokine production by acetate supplementation or histone deacetylase inhibition established acetyl-CoA–dependent histone acetylation as a mechanistic link between metabolic flux and effector function. Conversely, the cytokine interleukin-21 enhanced T H 1 cell effector activity by promoting a GSK3β-dependent shift from OXPHOS to glycolysis. Single-cell transcriptomic analysis of Crohn’s disease tissue revealed enrichment of glycolytic gene programs in nonregulatory CD4 + T cells. Consistent with these findings, pharmacologic inhibition of GSK3β attenuated disease severity in a T cell–transfer mouse model of colitis. Together, these findings identify a GSK3β-dependent metabolic-epigenetic axis that sustains T H 1 cell pathogenicity and highlight GSK3β as a potential therapeutic target for IBD.
Updates in the diagnosis of interstitial lung disease: evolving concepts and terminology
Maule, Geran, Lee, Augustine, Ryu, Jay

Mayo Clinic

Expert Review of Respiratory Medicine | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.1080/17476348.2026.2736889 | PMID 42803636 Get It

PATIENT SATISFACTION FOLLOWING UROLOGY RETURN VISITS BASED ON PROVIDER TYPE
Kahn, Amanda E. , Qosja, Neda, Spaulding, Aaron , Bews, Katie, Cardona, Kathryn, Lee, Yeonsoo Sara , Geldmaker, Laura , McCoy, Katherine , Zhang, Jaine, Thiel, David D. , Kahn, Amanda

Mayo Clinic

Urology Practice | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/upj.0000000000001095 | PMID 42782709 Get It

Assessment of Fairness and Bias of an Image-based Surgical Site Infection Detection AI Model
Lee, Frank G. , Choudhary, Ashok , Li-Han, Leo Yan , Dale, Erica L., Bankes, Audrey C , Varghese, Chris , Anderson, Stephanie S., Habermann, Elizabeth B. , Etzioni, David A. , McLaughlin, Sarah A. , Salehinejad, Hojjat , Thiels, Cornelius A. , Varghese, Chris , Habermann, Elizabeth , Dale, Erica , Bankes, Audrey , Choudhary, Ashok , Lee, Frank G

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.22.26363636 Get It

ABSTRACT Background Evaluating fairness in artificial intelligence (AI) is essential before clinical implementation to prevent unintended harm across diverse patient populations. This study assesses performance differences of an image-based surgical site infection (SSI) detection model across age, gender, geography, race, and skin color. Methods Model development/validation study using retrospective, multicenter data across surgical subspecialties from adults who submitted an image of their incision via the electronic health record within 30 days of their procedure between 2019-2024. Area under receiver operating curve (AUROC) was compared by age (<55 vs. ≥55 years old), gender (male vs. female), geography (Rochester, Minnesota vs. Jacksonville, Florida vs. Scottsdale, Arizona vs. regional Minnesota/Wisconsin areas), race (White/Caucasian vs. non-White/Caucasian), and skin color (Fitpatrick I-III vs. IV-VI and Monk A-E vs. F-J). Results Training data contained 13,702 images from 4,274 patients between 2019-2022 (50.1% ≥55 years old; 63.2% female; 91.6% White/Caucasian; 58.5% Rochester, 17.3% Florida, 10.5% Arizona; 96.3% light skin tone), of which 1,348 images (9.8%) had an SSI. No differences in SSI detection existed for age, gender, race, or skin color (AUROC 0.83-0.87, p>0.09), however geographical differences were significant: lowest AUROC 0.83 (95% CI 0.77-0.88) vs. highest AUROC 0.87 (95% CI 0.84-0.89, p=0.01). Temporal validation using 4,242 images from 1,353 patients between 2022-2023 showed intact fairness across subgroups (ΔAUROC ≤0.06) except geography (ΔAUROC ≤0.16). Conclusions The model behaved fairly across age, gender, race, and skin color, however geographical differences persisted. These findings have practical implications underscoring the importance of evaluating bias in clinical AI before deployment.
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Artificial Intelligence Enabled Diagnostics Using Photoplethysmography (PPG): Beyond SpO2 and Heart Rate
Joshi, Divya Dinesh, Saraboji, Kaaviyashri , Shaik, Asiya Tasleema , Sakalabaktula, Krishna Sai Kiran, Purohit, Shreya, Godugu, Swathi , Nirmal, Jasmine , Kayarkar, Riya, Correa, Bernardo Henrique Mendes , Gangidi, Namratha , Yadav, Pratibha, Yadav, Jyoti , Farook, Farshi , LEE, JIEUN , Shariff, Mohammed Naveed , Sundaram, Divaakar Siva Baala, Yerrapragada, Gayathri, Elangovan, Poonguzhali , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Wilson, Sancia Mary Jerold, Karuppiah, Shiva Sankari, Abbasi, Zoma, Rapolu, Swetha, Bumrah, Simardeep Kaur, Bilgaiyan, Rashi, Premkumar, Chandra Rupini , Kaur, Anmolpreet , Pugalenthi, Lakshmi Sree , Sood, Divyanshi, Shivaram, Suganti, Iyer, Vivek , Vidhya, C. M., Masihi, Simin, Helgeson, Scott A. , Arunachalam, Shivaram P. , Natarajan, Thangeswaran , Jerold Wilson, Sancia Mary, Iyer, Vivek N , C M, Vidhya, Elangovan, Poonguzhali , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Sakalabaktula, Krishna Sai Kiran , Godugu, Swathi , Yerrapragada, Gayathri, Bumrah, Simardeep Kaur, Bilgaiyan, Rashi , Shivaram, Suganti, Masihi, Simin

Mayo Clinic

Life | September 15, 2026 | Volume: 16 | Issue: 9 | Pages: 1530

10.3390/life16091530 | PMID 42795395 Get It

Photoplethysmography (PPG) is a non-invasive optical technique commonly used to measure heart rate and oxygen saturation, but its waveform contains additional physiological information that can be analyzed using artificial intelligence (AI). This narrative review summarizes the emerging applications of AI-based PPG in cardiovascular, respiratory, sleep, hemodynamic, pregnancy-related, and portal-hypertension assessment, with the aim of evaluating its potential beyond conventional monitoring and identifying barriers to clinical translation. The literature search was conducted using PubMed, Google Scholar, IEEE Xplore, ScienceDirect, and SpringerLink. Additional relevant studies were identified through screening the reference lists of included articles. Studies published between 2002 and 2026 were identified to capture the development of PPG from conventional monitoring to newer AI-based applications. Human studies were prioritized, while relevant computational, simulated, synthetic, ex vivo, and technical studies were also included. Studies unrelated to PPG, duplicates, and studies with limited relevance were excluded. A total of 96 references were included, covering AI approaches such as convolutional and deep neural networks, ensemble methods, transfer learning, U-Net, generative adversarial networks, and Transformer-based models. Overall, the reviewed evidence suggests that AI-based PPG may support blood pressure estimation, atrial fibrillation detection, sleep and respiratory monitoring, vascular aging assessment, pulmonary hypertension screening, preeclampsia assessment, volume-status and compensatory-reserve assessment, and exploratory assessment related to portal hypertension. However, clinical translation remains limited by motion artifacts, sensor and measurement-site variability, skin-pigmentation-related bias, physiological and environmental influences, heterogeneous methods, limited external validation, and inconsistent clinical and regulatory standards.
Prospective randomised double‐blind trial: holmium laser lithotripsy with vs without Moses™ 2.0
Lee, Matthew , Forbes, Connor M. , Koyama, Tatsuki , Maciolek, Kimberly A , Nimmagadda, Naren , Lee, Aaron X , Hsi, Ryan , Koyama, Tatsuki , Forbes, Connor M , Lee, Matthew S , Chehroudi, Cyrus , Margolin, Ezra J , Chew, Ben H , Shah, Ojas , Miller, Nicole L , Nimmagadda, Naren , Reed, Amy M., Hsi, Ryan S. , Chew, Ben H. , Bechis, Seth K. , Humphreys, Mitchell R. , Lipkin, Michael E. , Monga, Manoj , Shah, Ojas , Stern, Karen , Sur, Roger L. , Sivalingam, Sri , Miller, Nicole L.

Mayo Clinic

BJU International | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bju.70446 | PMID 42733216 Get It

Objective To assess the effect of Moses™ 2.0 (Lumenis Be Ltd., Yokneam Illit, Israel; Boston Scientific, Marlborough, MA, USA) for lithotripsy of renal stones of 8–20 mm in diameter on operative time, surgeon workload, and retropulsion. Subjects/Patients and Methods In our multicentre, randomised, double‐blind clinical trial, patients were randomised 1:1 to standard or Moses 2.0 laser lithotripsy and stratified by stone size. Patients and surgeons were blinded to laser modality. Primary outcomes were total operative time as well as surgeon workload assessed by the National Aeronautics and Space Administration‐Task Load Index (NASA‐TLX). Secondary outcomes were stone retropulsion evaluated by blinded video review and postoperative clinical outcomes. Linear regression modelling was used for analysis. Results A total of 153 patients (79 Standard, 74 Moses 2.0) with similar clinical, stone, and operative characteristics were evaluated. There was no significant difference in operative times between the Standard and Moses 2.0 groups ( P = 0.73). Moses 2.0 was associated with lower effort, frustration, mental, physical, and temporal workload, as well as higher rated overall performance compared to the standard laser. Video review demonstrated no difference in rates of retropulsion ( P = 0.13). Complication rates (Standard: 13%; Moses 2.0: 10%) and stone‐free rates (Standard: 51%; Moses: 2.0 55%) were comparable. Conclusion Our study evaluated the impact of Moses 2.0 technology on high‐powered renal stone dusting, constituting the largest double‐blind trial of its kind to date. There was insufficient evidence to suggest any difference in operative times or clinical outcomes when using Moses 2.0 compared to standard laser lithotripsy. Moses 2.0 was associated with reduced surgeon workload, which has implicit impact on surgeon wellness.
Cardiac Resynchronization Therapy and Circulating Metabolomic Profile in Patients With Advanced Heart Failure
Qian, Zhiyong , Lee, Hon-Chi , Mulpuru, Siva K. , Vučković, Ivan , Deshmukh, Abhishek , DeSimone, Christopher V. , Asirvatham, Samuel J. , Wen, Songnan, Li, Chuanwei , Zhang, Song , Dasari, Surendra, Dzeja, Petras P. , Yu, Bing , Bailey, Kent R. , Chen, Horng H. , Cha, Yong‐Mei , Deshmukh, Abhishek J , Lanza, Ian R , Yu, Bing , Bailey, Kent R , Chen, Horng , Cha, Yong-Mei , Asirvatham, Samuel J , DeSimone, Christopher V , Vuckovic, Ivan , Zhang, Song , Dasari, Surendra, Lanza, Ian R.

Mayo Clinic

Circulation: Heart Failure | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circheartfailure.125.014148 | PMID 42717876 Get It

BACKGROUND: It is unknown whether cardiac resynchronization therapy (CRT) improves systemic metabolomic profile by enhancing left ventricular function. The observational cohort study aimed to investigate the effect of CRT on left ventricular ejection fraction (LVEF) and circulating plasma metabolites in patients who had heart failure with reduced LVEF. METHODS: We prospectively screened patients with ischemic cardiomyopathy and nonischemic cardiomyopathy who received CRT with a defibrillator for LVEF ≤35% according to current guidelines. Clinical assessment included echocardiography and device interrogation. Blood samples for metabolomic analysis were collected before CRT and at 6-month follow-up. Plasma was subjected to gas chromatography-mass spectrometry and 1 H nuclear magnetic resonance-based metabolomic analysis. RESULTS: Totally 92 patients were enrolled, with a mean age of 67.3±11.3 years (37.0% female). LVEF was significantly improved from 28.9±7.6% at baseline to 36.0±11.3% at 6 months ( P <0.001) and to 40.1±12.6% at 12 months ( P <0.001). After CRT, 42 metabolite features were significantly decreased compared with the baseline. The ketone bodies, including 3-hydroxybutyrate ( P <0.001) and acetone ( P =0.01), were reduced. A branched-chain amino acid, isoleucine, was also decreased after CRT ( P =0.01). These metabolomic changes were mainly observed in the nonischemic cardiomyopathy group, while the metabolomic profile in the ischemic cardiomyopathy group was characterized by enhanced amino acid oxidation and elevated levels of lactate and pyruvate. The improvement in LVEF positively correlated with the ratio of changes in ketone bodies and isoleucine. CONCLUSIONS: CRT may modulate the systemic plasma metabolomic profile, which correlated with improvement in left ventricular function in patients with severe heart failure with reduced ejection fraction.
Electrochemical immunosensor-enabled liquid biopsy of extracellular vesicles for diagnosis of metabolic dysfunction-associated steatohepatitis
Nguyen, Thi Thanh Qui, Lee, Seonhwa , Mauer, Amy S. , Giron, Anthony, Cedillo‐Alcantar, Diana F. , Graham, Rondell, Allen, Alina, Revzin, Alexander, Choi, Daheui , Hoyos‐Vega, José M. de , Daniel, P. Vineeth , Eller, Michael J. , Stybayeva, Gulnaz , Lazaridis, Konstantinos , Malhi, Harmeet , Revzin, Alexander

Mayo Clinic

No container title available | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.26362088 | PMID 42818423 Get It

Abstract Accurate, noninvasive biomarkers for diagnosis and longitudinal monitoring of metabolic dysfunction–associated steatohepatitis (MASH) remain an urgent unmet clinical need. Here, we describe an electrochemical immunoassay that involves capturing hepatic extracellular vesicles (EVs) on antibody-modified electrodes followed by detecting EV-borne biomarkers using redox active gold nanoparticles (AuNPs). The intensity of electrochemical redox signal represents a quantitative measure of biomarker abundance. Three MASH-associated biomarkers—S100A11, TNF-α, and TGF-β1—were analyzed on hepatic EVs to assess steatotic, inflammatory, and fibrotic states of the diseased liver. The electrochemical signals for individual biomarkers were added into a composite EV MASH score. Plasma samples from 28 patients with MASH, 22 healthy controls, and 27 patients with non-MASH liver disease were scored in this manner, revealing 100% accuracy in the training cohort and >90% accuracy in an independent validation cohort. Our electrochemical immunosensor represents a minimally invasive liquid liver biopsy, offering a promising alternative to solid liver biopsies for screening and monitoring of MASH. One Sentence Summary Circulating hepatic extracellular vesicles carry biomarkers of liver injury enabling accurate, minimally invasive MASH diagnosis in blood.
Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer
Jin, Ling, Balakrishnan, Karthik , Hou, Xiaonan , VanBlaricom, Jamison L., Lee, Sun-Hee, Oberg, Ann L. , Weroha, John, Shridhar, Viji, Thirusangu, Prabhu , Jin, Ling, Rao, Shruti , Balakrishnan, Karthik, Lee, Sun-Hee , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N. , Shridhar, Viji

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.748933 | PMID 42922689 Get It

Abstract Therapeutic resistance in ovarian cancer is frequently driven by persistent replication stress, yet the molecular mechanisms that convert replication stress into a therapeutically exploitable vulnerability remain incompletely understood. Here, we identify drug-induced nuclear cathepsin L (nCTSL) as a previously unrecognized regulator of replication stress and DNA repair. Clofarabine (CLF) combined with the ATR inhibitor AZD6738, or the CHK1 inhibitor prexasertib promoted nuclear accumulation of CTSL, where it remodeled the replication machinery through degradation of CCNE1, MCM3, MCM6, and geminin, accompanied by loss of RAD51 and 53BP1 and increased γH2AX and phospho-RPA2. DNA fiber analysis demonstrated marked inhibition of replication fork progression following CLF-based combinations, whereas CTSL depletion accelerated fork progression and abolished therapy-induced replication stress. Reconstitution with the nuclear M1F CTSL isoform restored replication restraint, confirming a direct role for nuclear CTSL in regulating replication dynamics. GFP-based DNA repair reporter assays further revealed that CLF-based combinations suppress DNA repair competence in a CTSL-dependent manner, indicating that nuclear CTSL couples replication stress amplification with functional inhibition of repair pathways. Functionally, CLF-based combinations selectively targeted transformed fallopian tube secretory epithelial cells while sparing non-transformed counterparts, demonstrated broad activity in patient-derived ovarian cancer ascites spheroids, and significantly inhibited tumor growth and prolonged survival in vivo . Collectively, our findings identify nuclear CTSL as a mechanistic driver of replication stress that remodels the replication machinery, impairs DNA repair, and creates a therapeutically exploitable vulnerability in ovarian cancer. We propose that nuclear CTSL promotes a transition from replication competence to replication catastrophe, thereby establishing a conceptual framework for biomarker-guided therapeutic strategies targeting CTSL-dependent replication stress.